Repercussions of growing short-termism
Merger set to complete 14 August
A Q&A with BB Biotech's Head of Investment Management Daniel Koller reveals how innovation in medicine is offering investment opportunities.
Regulatory costs expected to double in five years
Based on findings in FCA suitability review
Response to FCA Study
Industry is 'too disparate'